These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 17414400)

  • 21. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
    Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
    Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
    Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
    Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
    Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
    N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
    Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
    Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.
    de Kleijn ED; de Groot R; Lafeber AB; Labadie J; van Limpt CJ; Visser J; Berbers GA; van Alphen L; Rümke HC
    J Infect Dis; 2001 Jul; 184(1):98-102. PubMed ID: 11398116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
    Trotter C; Findlow J; Balmer P; Holland A; Barchha R; Hamer N; Andrews N; Miller E; Borrow R
    Clin Vaccine Immunol; 2007 Jul; 14(7):863-8. PubMed ID: 17494636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
    Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
    Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.